Olanzapine Pharmacokinetics: A Clinical Review of Current Insights and Remaining Questions

Priyanka Kolli, Grace Kelley, Marianela Rosales, Justin Faden, Ryan Serdenes
{"title":"Olanzapine Pharmacokinetics: A Clinical Review of Current Insights and Remaining Questions","authors":"Priyanka Kolli, Grace Kelley, Marianela Rosales, Justin Faden, Ryan Serdenes","doi":"10.2147/pgpm.s391401","DOIUrl":null,"url":null,"abstract":"<strong>Abstract:</strong> Olanzapine is one of the most widely used antipsychotics since its initial approval by the US Food and Drug Administration in 1996 and has undergone extensive pharmacokinetic study. Despite being utilized in clinical psychiatry for decades, there remain questions regarding the variety of available formulations, the utility of therapeutic drug monitoring, altered kinetic properties in special populations/medical illnesses, the use of high-dose olanzapine, and drug interactions, among many others. We performed a narrative literature review of olanzapine pharmacokinetics in June 2023 using the US National Library of Medicine’s PubMed.gov resource (<u>https://www.ncbi.nlm.nih.gov/pubmed</u>) and Google Scholar. Herein, we review clinically relevant aspects of olanzapine pharmacokinetic data while highlighting knowledge gaps and potential areas of future study.<br/><br/><strong>Keywords:</strong> olanzapine, pharmacokinetics, drug-drug interactions, pharmacodynamics, clinical psychopharmacology<br/>","PeriodicalId":501056,"journal":{"name":"Pharmacogenomics and Personalized Medicine","volume":"97 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacogenomics and Personalized Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/pgpm.s391401","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract: Olanzapine is one of the most widely used antipsychotics since its initial approval by the US Food and Drug Administration in 1996 and has undergone extensive pharmacokinetic study. Despite being utilized in clinical psychiatry for decades, there remain questions regarding the variety of available formulations, the utility of therapeutic drug monitoring, altered kinetic properties in special populations/medical illnesses, the use of high-dose olanzapine, and drug interactions, among many others. We performed a narrative literature review of olanzapine pharmacokinetics in June 2023 using the US National Library of Medicine’s PubMed.gov resource (https://www.ncbi.nlm.nih.gov/pubmed) and Google Scholar. Herein, we review clinically relevant aspects of olanzapine pharmacokinetic data while highlighting knowledge gaps and potential areas of future study.

Keywords: olanzapine, pharmacokinetics, drug-drug interactions, pharmacodynamics, clinical psychopharmacology
奥氮平药代动力学:当前见解和遗留问题的临床回顾
摘要:奥氮平自 1996 年获得美国食品和药物管理局首次批准以来,一直是使用最广泛的抗精神病药物之一,并进行了广泛的药代动力学研究。尽管奥氮平已在临床精神病学领域应用了数十年,但仍存在许多问题,包括现有制剂的多样性、治疗药物监测的效用、特殊人群/医疗疾病中动力学特性的改变、大剂量奥氮平的使用以及药物相互作用等等。2023 年 6 月,我们利用美国国立医学图书馆的 PubMed.gov 资源 (https://www.ncbi.nlm.nih.gov/pubmed) 和 Google Scholar 对奥氮平药代动力学进行了叙述性文献综述。在此,我们回顾了奥氮平药代动力学数据的临床相关方面,同时强调了知识差距和未来研究的潜在领域。关键词:奥氮平;药代动力学;药物相互作用;药效学;临床精神药理学
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信